| |
| |
|
| Insider
Information: |
Elms Steve |
| Relationship: |
Director |
| City: |
Chester |
| State: |
NJ |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
16 |
|
| Direct
Shares |
2,319,032 |
|
|
Indirect Shares
|
52,249,428 |
|
|
| Direct
Value |
$1,079,634 |
|
|
|
Indirect Value
|
$42,444,139 |
|
|
| Total
Shares |
54,568,460 |
|
|
| Total
Value |
$43,523,773 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
1
|
5
|
|
Stock
price went up :
|
1
|
5
|
| Stock
price went down : |
0
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
1.0
|
5.0
|
| Percentage
Gain/Loss : |
 57.8%
|
29.8%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Map Pharmaceuticals Inc |
MAPP |
Director |
2010-03-10 |
0 |
2010-02-11 |
0 |
Premium* |
|
|
Zeltiq Aesthetics Inc |
ZLTQ |
10% Owner |
2014-01-23 |
2,398 |
2014-01-23 |
2,597,742 |
Premium* |
|
|
Pernix Therapeutics Holdings |
PTX |
Director |
2012-03-22 |
10,000 |
2012-03-22 |
2,000,000 |
Premium* |
|
|
Melinta Therapeutics, Inc |
MLNT |
10% Owner |
|
0 |
2012-02-07 |
3,293,060 |
Premium* |
|
|
ADMA Biologics Inc |
ADMA |
|
2024-03-19 |
76,441 |
2024-03-19 |
2,115,671 |
Premium* |
|
|
Durata Therapeutics, Inc. |
DRTX |
10% Owner |
2014-05-20 |
6,182 |
2014-03-21 |
3,030,175 |
Premium* |
|
|
Esperion Therapeutics, Inc. |
ESPR |
10% Owner |
2013-07-01 |
0 |
2015-04-24 |
1,837,125 |
Premium* |
|
|
Asensus Surgical Inc |
ASXC |
10% Owner |
|
0 |
2014-04-21 |
8,335,819 |
Premium* |
|
|
Agile Therapeutics Inc |
AGRX |
10% Owner |
2014-05-23 |
2,171,831 |
|
0 |
Premium* |
|
|
Loxo Oncology, Inc. |
LOXO |
Director, 10% Owner |
|
0 |
2019-02-15 |
2,038,920 |
Premium* |
|
|
T2 Biosystems, Inc. |
TTOO |
10% Owner |
2014-08-12 |
0 |
2014-08-12 |
2,523,300 |
Premium* |
|
|
Cidara Therapeutics, Inc. |
CDTX |
Director |
|
0 |
2015-04-20 |
1,054,610 |
Premium* |
|
|
Viewray, Inc. |
VRAY |
10% Owner |
|
0 |
2016-03-30 |
7,461,923 |
Premium* |
|
|
Viracta Therapeutics Ord Shs |
VIRX |
10% Owner |
2019-07-15 |
0 |
2019-07-15 |
10,100,000 |
Premium* |
|
|
Marker Therapeutics Inc |
MRKR |
Director |
2021-06-08 |
29,680 |
2021-06-08 |
3,142,857 |
Premium* |
|
|
Zosano Pharma Corp |
ZSAN |
Director |
2021-06-10 |
22,500 |
2021-06-10 |
2,718,226 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
25 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| ADMA |
ADMA Biologics Inc |
|
• • – |
2024-03-19 |
4 |
S |
$6.08 |
$2,503,920 |
I/I |
(411,829) |
2,115,671 |
0 |
% |
|
| ADMA |
ADMA Biologics Inc |
|
• • – |
2024-03-18 |
4 |
S |
$6.01 |
$299,821 |
I/I |
(49,887) |
2,527,500 |
0 |
% |
|
| ADMA |
ADMA Biologics Inc |
|
• • – |
2024-03-15 |
4 |
S |
$6.01 |
$1,099,878 |
I/I |
(183,008) |
2,577,387 |
0 |
% |
|
| ADMA |
ADMA Biologics Inc |
|
• • – |
2024-03-14 |
4 |
S |
$6.05 |
$2,712,070 |
I/I |
(448,276) |
2,760,395 |
0 |
% |
|
| ADMA |
ADMA Biologics Inc |
|
• • – |
2024-03-13 |
4 |
S |
$6.21 |
$2,527,470 |
I/I |
(407,000) |
3,208,671 |
0 |
% |
|
| ADMA |
ADMA Biologics Inc |
|
• • – |
2024-02-26 |
4 |
A |
$0.00 |
$0 |
D/D |
24,040 |
76,441 |
0 |
- |
|
| ADMA |
ADMA Biologics Inc |
|
• • – |
2023-03-06 |
4 |
A |
$0.00 |
$0 |
D/D |
25,815 |
52,401 |
0 |
- |
|
| ADMA |
ADMA Biologics Inc |
|
• • – |
2022-03-07 |
4 |
A |
$0.00 |
$0 |
D/D |
26,586 |
26,586 |
0 |
- |
|
| ZSAN |
Zosano Pharma Corp |
Director |
– • – |
2021-06-10 |
4 |
A |
$0.00 |
$0 |
D/D |
15,000 |
22,500 |
0 |
- |
|
| MRKR |
Marker Therapeutics Inc |
Director |
– • – |
2021-06-08 |
4 |
A |
$0.00 |
$0 |
D/D |
12,658 |
29,680 |
0 |
- |
|
| MRKR |
Marker Therapeutics Inc |
Director |
– • – |
2021-03-16 |
4 |
B |
$1.75 |
$2,000,000 |
I/I |
1,142,857 |
3,142,857 |
2.1 |
- |
|
| ADMA |
ADMA Biologics Inc |
Director |
– • – |
2020-02-28 |
4 |
A |
$0.00 |
$0 |
D/D |
7,500 |
7,500 |
0 |
- |
|
| MRKR |
Marker Therapeutics Inc |
Director |
– • – |
2019-08-06 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
2,000,000 |
|
- |
|
| VIRX |
Viracta Therapeutics Ord ... |
10% Owner |
– – • |
2019-07-15 |
4 |
B |
$0.60 |
$1,500,000 |
I/I |
2,500,000 |
10,100,000 |
1.5 |
- |
|
| LOXO |
Loxo Oncology, Inc. |
Director |
– • • |
2019-02-15 |
4 |
D |
$235.00 |
$479,146,200 |
I/I |
(2,038,920) |
2,038,920 |
0 |
- |
|
| VRAY |
Viewray, Inc. |
10% Owner |
– – • |
2016-03-30 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
7,461,923 |
|
- |
|
| ESPR |
Esperion Therapeutics, In... |
10% Owner |
– – • |
2015-04-24 |
4 |
S |
$106.10 |
$7,169,373 |
I/I |
(67,469) |
1,837,125 |
0 |
- |
|
| ESPR |
Esperion Therapeutics, In... |
10% Owner |
– – • |
2015-04-23 |
4 |
S |
$109.10 |
$16,365,000 |
I/I |
(150,000) |
1,904,594 |
0 |
- |
|
| CDTX |
Cidara Therapeutics, Inc. |
Director |
– • – |
2015-04-20 |
4 |
A |
$0.00 |
$0 |
I/I |
351,518 |
351,518 |
0 |
- |
|
| CDTX |
Cidara Therapeutics, Inc. |
Director |
– • – |
2015-04-14 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
703,092 |
|
- |
|
| TTOO |
T2 Biosystems, Inc. |
10% Owner |
– – • |
2014-08-12 |
4 |
B |
$11.00 |
$4,999,995 |
I/I |
454,545 |
2,523,300 |
1.5 |
- |
|
| TTOO |
T2 Biosystems, Inc. |
10% Owner |
– – • |
2014-08-12 |
4 |
A |
$0.00 |
$0 |
I/I |
2,068,755 |
2,068,755 |
0 |
- |
|
| LOXO |
Loxo Oncology, Inc. |
Director |
– • • |
2014-08-06 |
4 |
B |
$13.00 |
$5,370,001 |
I/I |
413,077 |
3,452,493 |
2.25 |
- |
|
| LOXO |
Loxo Oncology, Inc. |
Director |
– • • |
2014-08-06 |
4 |
A |
$0.00 |
$0 |
I/I |
2,850,709 |
3,039,416 |
0 |
- |
|
| LOXO |
Loxo Oncology, Inc. |
Director |
– • • |
2014-07-31 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
188,707 |
|
- |
|
25 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
